000143817 001__ 143817
000143817 005__ 20240229112609.0
000143817 0247_ $$2doi$$a10.1093/neuonc/noz057
000143817 0247_ $$2pmid$$apmid:30943283
000143817 0247_ $$2ISSN$$a1522-8517
000143817 0247_ $$2ISSN$$a1523-5866
000143817 0247_ $$2altmetric$$aaltmetric:58446747
000143817 037__ $$aDKFZ-2019-01379
000143817 041__ $$aeng
000143817 082__ $$a610
000143817 1001_ $$0P:(DE-He78)2f592d9d8339bee07cca3956b7472b61$$aSchramm, Kathrin$$b0$$eFirst author
000143817 245__ $$aDECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for DIPGs.
000143817 260__ $$aOxford$$bOxford Univ. Press$$c2019
000143817 3367_ $$2DRIVER$$aarticle
000143817 3367_ $$2DataCite$$aOutput Types/Journal article
000143817 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681387505_19515
000143817 3367_ $$2BibTeX$$aARTICLE
000143817 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143817 3367_ $$00$$2EndNote$$aJournal Article
000143817 520__ $$aDiffuse intrinsic pontine gliomas (DIPGs) are highly aggressive pediatric brain tumors that are characterized by a recurrent mutation (K27M) within the histone H3 encoding genes H3F3A or HIST1H3A/B/C. These mutations have been shown to induce a global reduction in the repressive histone modification H3K27me3, which together with widespread changes in DNA methylation patterns results in an extensive transcriptional reprogramming hampering the identification of single therapeutic targets based on a molecular rationale.We applied a large-scale gene knockdown approach using a pooled shRNA library in combination with next-generation sequencing in order to identify DIPG-specific vulnerabilities. The therapeutic potential of specific inhibitors of candidate targets was validated in a secondary drug screen.We identified fibroblast growth factor receptor (FGFR) signaling and the serine/threonine protein phosphatase 2A (PP2A) as top depleted hits in patient-derived DIPG cell cultures and validated their lethal potential by FGF ligand depletion and genetic knockdown of the PP2A structural subunit PPP2R1A. Further, pharmacological inhibition of FGFR and PP2A signaling through ponatinib and LB-100 treatment, respectively, exhibited strong tumor-specific anti-proliferative and apoptotic activity in cultured DIPG cells.Our findings suggest FGFR and PP2A signaling as potential new therapeutic targets for the treatment of DIPGs.
000143817 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000143817 588__ $$aDataset connected to CrossRef, PubMed,
000143817 7001_ $$0P:(DE-He78)f28fcc92d5c00f3ee511e3319c699b38$$aIskar, Murat$$b1
000143817 7001_ $$0P:(DE-He78)5f5223d7faa01a1e1df8a30d85cff5b0$$aStatz, Britta$$b2
000143817 7001_ $$0P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aJäger, Natalie$$b3
000143817 7001_ $$0P:(DE-He78)4e91a6c1d8301c9e964b25e084804264$$aHaag, Daniel$$b4
000143817 7001_ $$0P:(DE-HGF)0$$aSłabicki, Mikołaj$$b5
000143817 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b6
000143817 7001_ $$0P:(DE-He78)1beba8f953e7ae7e96e8d3e9a48f10f7$$aZapatka, Marc$$b7
000143817 7001_ $$0P:(DE-He78)bb186a8b38fef24ebd6f11918ade985d$$aGronych, Jan$$b8
000143817 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T W$$b9$$eLast author
000143817 7001_ $$0P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c$$aLichter, Peter$$b10$$eLast author
000143817 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noz057$$n7$$p867-877$$tNeuro-Oncology$$v21$$x1523-5866$$y2019
000143817 909CO $$ooai:inrepo02.dkfz.de:143817$$pVDB
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2f592d9d8339bee07cca3956b7472b61$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f28fcc92d5c00f3ee511e3319c699b38$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5f5223d7faa01a1e1df8a30d85cff5b0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4e91a6c1d8301c9e964b25e084804264$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1beba8f953e7ae7e96e8d3e9a48f10f7$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb186a8b38fef24ebd6f11918ade985d$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000143817 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000143817 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000143817 9141_ $$y2019
000143817 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143817 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2017
000143817 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143817 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143817 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143817 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143817 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143817 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143817 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143817 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143817 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2017
000143817 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lB060 Molekulare Genetik$$x0
000143817 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000143817 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPediatric Glioma$$x2
000143817 980__ $$ajournal
000143817 980__ $$aVDB
000143817 980__ $$aI:(DE-He78)B060-20160331
000143817 980__ $$aI:(DE-He78)B062-20160331
000143817 980__ $$aI:(DE-He78)B360-20160331
000143817 980__ $$aUNRESTRICTED